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Background: Cancer represents a significant source of morbidity and mortality in people living 
with HIV/AIDS (PLWHA) and risk of most cancer exceeds that observed in the general 
population. A substantial proportion of cancers in PLWHA may be attributable to infection, with 
risk largely due to HIV-related immune deficiency and co-infection with oncogenic pathogens. 
p53 is a tumor suppressor also involved in innate immune signaling via the Toll-like receptor 8 
(TLR8). SNPs in both the TP53 (rs1042522) and TLR8 (rs3764880) genes may mediate the innate 
immune response, with the TP53 G and TLR8 A alleles hypothesized to be jointly protective 
against cancer. 
Methods: Seven hundred and sixty participants enrolled in the Multicenter AIDS Cohort Study 
(MACS) provided blood samples for ascertainment of SNP genotypes. Outcomes assessed were 
diagnosis of any cancer, AIDS-defining cancer, non-AIDS-defining cancer, and infection-related 
cancer up to two years after participants’ last visits. Exact Poisson regression was used to estimate 
unadjusted and adjusted incidence rate ratios associated with SNP genotypes for each outcome. 
Joint SNP effects were estimated using an interaction term. 
Results: SNPs were found to be jointly protective against any cancer (interaction IRR: 0.46, 95% 
CI: 0.01-42.71), ADCs (interaction IRR: 0.47, 95% CI: 0.01-48.55), and infection-related cancers 
(interaction IRR: 0.40, 95% CI: 0.01-39.37) in multivariable models while main effects of SNPs 
were slightly protective or had no effect for all outcomes. 
Discussion: These findings are consistent with a hypothesized synergistic effect of SNPs on the 
immune response. Weak main SNP effects and strong interaction indicate a protective effect of 
SNPs only in the presence of each other. Future work will address missing data using imputation 
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HIV/AIDS and Treatments 
Acquired Immune Deficiency Syndrome (AIDS) was first identified in the early 1980s in men who 
have sex with men afflicted with opportunistic infections and rare cancers usually associated with 
profound immunosuppression.1 Not long after, multiple groups identified the causative agent to be 
the human immunodeficiency virus (HIV), a lentivirus of the retrovirus family.2-6 As a member of 
the retrovirus family, HIV is an enveloped virus with an RNA genome that is reverse-transcribed 
to DNA by a viral reverse transcriptase enzyme.6 The targets and mechanism of infection, namely 
T-cells expressing the CD4 surface antigen via either the CCR5 or CXCR4 co-receptor, were 
elucidated in the following years.7-11 It was also established that HIV transmission occurs through 
mucosal contact with infected body fluids, most commonly via unprotected sexual intercourse as 
well as via maternal-infant transmission or transmission among injection drug users.12,13 Upon 
infection, the virus is initially undetectable for up to several weeks, followed by rapid replication 
and increasing viral load, destruction and progressive decline of CD4+ cells, and resultant 
characteristic immunodeficiency.12,13 
Since its emergence, HIV/AIDS has spread worldwide, infecting tens of millions and inflicting 
significant morbidity and mortality, with the highest burden present in sub-Saharan Africa.13,14 
The discoveries of HIV, its targets, and its mechanism of action spurred drug development, 
resulting in the identification and approval of several classes of drugs found to slow progression 
of disease.15,16 The first drug approved for HIV in 1987 was azidothymidine (AZT), a nucleoside 
analog reverse-transcriptase inhibitor (NRTI), however, resistance was found to develop rapidly 
in those who responded to treatment.17,18 In subsequent years, several additional drugs of the NRTI 





protease inhibitors (PI), with saquinavir the first to be approved in 1995. The observation of 
resistance developing following treatment prompted investigations of combination treatments, 
with combination therapy of NRTI and PI found to be more effective than treatment with NRTI 
alone.19 Not long after, the first non-nucleoside analog reverse transcriptase inhibitor (NNRTI), 
nevirapine, was approved and added to the growing list of combination therapies under 
investigation, culminating in the first regimen of highly active anti-retroviral therapy (HAART) in 
1996.20,21 The combination regimen constituting HAART has evolved over time as new more 
effective agents and classes, such as integrase inhibitors, have become available, but the initial 
introduction of HAART remains a monumental juncture in the HIV/AIDS epidemic.22 
Global incidence peaked shortly after the introduction of HAART with 3.4 million new infections 
in 1996 and subsequently declined to 2.6 million new infections in 2005 and 1.8 million new 
infections in 2017.13,14,23 Meanwhile, AIDS-related deaths peaked at 1.9 million deaths worldwide 
in 2004 and decreased to just under one million deaths in 2017.13,23 Effective treatment for HIV 
has reduced incidence of new cases and mortality, resulting in a growing population of people 
living with HIV/AIDS (PLWHA) which numbered almost 37 million people in 2017.23 
The introduction of effective combination therapy ushered in the HAART era and resulted in an 
epidemiologic shift in PLWHA, with significant reduction in deaths due to AIDS-related causes, 
prolonged survival, and with adequate access and adherence to HAART, the rise of the idea of 
HIV as a chronic disease.13,24-27 However, with increasing survival and an aging population of 
PLWHA in the HAART era, it has been observed that this population is at elevated risk for 
numerous non-AIDS-related morbidities compared to the general population, including 






Cancer in People living with HIV/AIDS 
Cancers represent a significant source of morbidity and mortality in PLWHA. Risks of most 
cancers exceed risk observed in the general population and cancer accounts for 20-30% of deaths 
in this population.32-38 Elevated risk of cancer in PLWHA compared to the general population can, 
depending on the cancer type, be attributed to several factors, including frequent co-infection with 
oncogenic pathogens,39-41 immune deficiency or dysregulation related to HIV,42-44 and a higher 
prevalence of certain lifestyle-related risk factors for cancer in PLWHA, such as smoking,38,45 
alcohol use and abuse among certain sub-populations,46,47 and potentially metabolic syndrome 48,49 
which often arises due to HAART-related metabolic perturbations.50,51 
Cancers in PLWHA are classified as AIDS-defining cancers (ADCs) or non-AIDS-defining 
cancers (NADCs) and demonstrate variable epidemiologic trends since the emergence of HIV and 
AIDS and their treatments.52 The category of ADCs – consisting of Kaposi sarcoma (KS), non-
Hodgkin lymphoma (NHL), and cervical cancer – is defined as such due to the early inclusion of 
these cancers in case definitions of AIDS.1,53,54 The development of KS and cervical cancer in 
PLWHA occur as a consequence of coinfection with Kaposi sarcoma-associated herpesvirus 
(KSHV, also known as human herpesvirus-8) and human papilloma virus (HPV), respectively.41,55 
NHL, in contrast, is a more heterogeneous disease and different subtypes have been associated 
with several viral infections; including primary effusion lymphoma with KHSV,56,57 multiple 
lymphoma subtypes with Epstein-Barr virus (EBV),58,59 and marginal zone lymphoma and diffuse 
large B-cell with hepatitis C virus (HCV);60,61 while many subtypes are often attributable to non-
infectious factors that may involve lifestyle and occupational exposures.62,63 
The category of NADCs consists of all cancers not included in ADCs and is not informative of 





cancers that have and have not been shown to have an infection-related etiology. Infection-related 
cancers among NADCs include cancers of the oral cavity, pharynx, and anogenital area excluding 
the cervix associated with HPV,64,65 Hodgkin lymphoma associated with EBV,66 liver cancer 
associated with viral hepatitis,67 lung cancer and pneumonia,68 and stomach cancer and 
Helicobacter pylori.69 The remaining cancers in the category are non-infection-related cancers, 
some of which (e.g. breast, colorectal, ovarian, and prostate cancer) have been reported to occur 
less frequently among PLWHA.70,71 Some of these findings remain topics of debate, such as 
reduced risk of prostate cancer being attributed to differential screening in separate studies,72,73 
while others, including the reduced risk of breast cancer, have taken root with potential 
mechanisms under investigation.74 
Infection-related cancers straddle the demarcation of ADCs and NADCs, including cancers from 
both classifications, and may represent a more informative categorization than traditional 
ADC/NADC dichotomization. Given the setting of impaired immunity in this population, the 
development of these malignancies in PLWHA is an area of ongoing research and concern. The 
burden due to infection-related cancer in PLWHA is high, with as many as 40% of all cancers 
attributable to infection and almost 70% of cancers among PLWHA in their 20s attributable to 
infection.75 Moreover, PLWHA are at significantly higher risk for infection-related ADCs and 
NADCs than the general population, although the degree of difference in risk has decreased in the 
HAART era.76 The availability of measures to prevent or treat infections associated with these 
cancers makes this area an opportunity for public health intervention to reduce cancer burden in 
PLWHA. 
In addition to its profound effects on disease progression and survival, HAART has also 





declined steadily since the introduction of HAART and cancer burden predominantly due to ADCs 
pre-HAART has given way to increasingly large burden due to NADCs in the HAART era.37,77-80 
Soon after the effectiveness of HAART was first demonstrated, it was shown that clinical and 
survival benefits were mediated by suppression of HIV viral load and recovery of immune cells 
and function.21,81 However, immune recovery may be incomplete among those initiating therapy 
with moderate or advanced disease82-84 and long-term impairments, including chronic 
inflammation as well as immune deficiency and dysregulation, may persist despite successful viral 
suppression and CD4+ cell recovery.85 The impaired immunological milieu in PLWHA may 
contribute to elevated risk of certain cancers, particularly infection-related malignancies, due to 
deficient immune response and reduced immune surveillance. A randomized trial comparing early 
initiation of HAART in asymptomatic HIV-infected individuals to deferment of initiation until a 
decrease of CD4+ cells below 350 cells per cubic millimeter found that early initiation resulted in 
a 60% reduction in hazard of any cancer, albeit at a median follow-up of only three years.86 
Secondary analysis of data from the same trial found a 74% reduction in hazard of infection-related 
cancer in early initiators compared to deferred initiators with suppression of viral load as a 
potential mediator of this relationship, again in spite of relatively short follow-up.87 A similar trial 
with a slightly different definition for initiation of deferred treatment observed relatively few 
incident cancers and no reduction in risk among early initiators at a median follow-up of two 
years.88 Observational studies have also shown that earlier initiation of therapy and better 
immunological response to therapy reduce risk of infection-related cancers.42-44,89,90 Finally, a 
meta-analysis comparing PLWHA and solid organ transplant recipients found similar patterns of 






In addition to immune deficits mediated by HIV and HAART, other modulators of immunity may 
contribute to risk of cancer among PLWHA. Non-heritable factors have been shown to be the 
primary determinants of immunity, however, genetic variants also contribute to immune function 
and can influence the immune response.92,93 The human immune system can be separated into the 
non-specific innate immune system and highly-specific adaptive immune systems. The innate 
immune system represents the first line of defense in which pattern-recognition elements identify 
common motifs in pathogens and initiate an immune response via activation of the complement 
system, recruitment of immune cells, and activation of the adaptive immune system.94 The 
adaptive immune system mounts a delayed but more robust and tailored response to pathogens 
through the generation of immune effector cells specific to antigens obtained from invading 
pathogens. This process also establishes immunological memory to enable a rapid adaptive 
immune response should infection with a given pathogen reoccur in the future.94 
The human immune system is a complex network of regulatory mechanisms, signaling pathways, 
and cellular interactions, among a multitude of other elements. The sum of these parts is a dynamic 
and well-tuned framework able to respond to both internal and external threats.94 Genetic variants 
in the immune system can disrupt or alter pathways within this network by affecting function or 
expression of its components, resulting in altered susceptibility to infection, autoimmunity, or 
immunodeficiency.95,96 
p53 
The transcription factor p53, most commonly known for its tumor suppressor functions and as a 
result dubbed the “guardian of the genome”, has also been found to exert transcriptional regulation 
on components of the innate immune system, notably those involved in antiviral immunity.97-101 





TP53 mutations identified in approximately half of all human cancers, while many germline 
variants have been found to be highly deleterious and associated with the Li-Fraumeni syndrome, 
a predisposition to early-onset cancer.102,103 Non-Li-Fraumeni germline variants, which modify but 
do not remove function, may impact the role of p53 in transcriptional control and downstream 
regulation of innate immunity. 
p53 was first discovered in in vitro studies of the oncogenic simian vacuolating virus 40 (SV40) 
and found to be the cellular target of SV40 large T antigen, the protein found to be necessary for 
SV40-mediated malignant transformation and subsequent tumor formation.104,105 Following its 
identification, researchers cloned and investigated the role of p53 in tumorigenesis, with several 
experiments demonstrating the capacity of p53 to transform cells in combination with the 
previously identified Ras oncogene, prompting hypotheses of p53 as the protein product of an 
oncogene.106-108 However, in subsequent years, it became clear that p53 proteins found to promote 
tumorigenesis were mutant forms and that the wildtype form is protective against tumors.109-110 
p53 was also found to be a cellular target of adenovirus E1 protein and the HPV E6 and E7 proteins 
with binding resulting in degradation of p53, establishing the role of p53 as a tumor suppressor by 
the end of the 1980s.111-113 More recently, the LANA protein of KSHV has also been found to 
inhibit p53 function.114 The targeting of p53 by viral proteins and subsequent degradation appears 
to constitute a viral mechanism enabling immune evasion, control of host cell machinery, and viral 
replication.115,116 Conversely, intact p53 may be necessary for replication of some other viruses.116 
p53 is a 53kD protein encoded by the TP53 gene located on the long arm of chromosome 17 and 
functions as a sequence-specific DNA-binding transcription factor.117,118 The TP53 gene contains 
multiple sites subject to post-transcriptional alternative splicing resulting in as many as fifteen 





isoform of p53 is a homotetramer of 393-amino acid peptides containing multiple domains which 
facilitate its broad interactions.120,121 The regulatory function of p53 extends to numerous cellular 
processes, including cell cycle regulation, apoptosis, senescence, and immune response, among 
many others.99-101,122,123  
The most extensively studied germline variant of TP53 is the codon 72 single nucleotide 
polymorphism (SNP). In this SNP, officially designated rs1042522, a cytosine (C) base appears 
instead of a guanosine (G) base, resulting in a proline residue (P72) replacing an arginine residue 
(R72).124 The location of this SNP is in a proline-rich region critical to p53’s role in apoptosis and 
growth suppression and it has been shown to influence p53 interactions, with R72 having a greater 
affinity for nuclear export, trafficking to mitochondria, and induction of apoptosis.125-129 
The mutant allele of rs1042522 is relatively common although allele frequencies appear to vary 
significantly across ancestral populations. Several studies have assessed the frequencies of the 
C/P72 and G/R72 alleles in different populations, finding that the frequency of the C allele 
increases incrementally with decreasing latitude, with prevalence of 15-25% among northern 
European populations, 35-55% in east Asians, 50-60% in south Asians, and 60-65% in equatorial 
African populations.130-132 Given these findings, it has been suggested that some latitude or 
temperature-based selection has taken place, potentially related to the association of this SNP with 
fertility at different temperatures.133,134 
Many population studies have assessed the effect of rs1042522 on risk of cancer with mixed 
results. Findings have included small suggestive association or no relationship with breast 
cancer135-138 as well as associations of the C/P72 allele with lung cancer in Asian smokers, non-
smokers, and a population of mixed smoking status;139-141 C/P72 with lung cancer in African-





bladder cancer in Asians but not Caucasians,144 C/P72 with endometrial cancer in Asian but not 
Caucasian women,145 G/R72 with slightly reduced risk of gastric cancer among Asians,146 and no 
association with risk of colorectal cancer.147 In addition, the G/R72 allele has been found to have 
a greater susceptibility to degradation mediated by HPV E6 protein and may increase risk of oral 
but not penile carcinoma among those infected with HPV.148-150 C/P72 has been associated with 
cervical cancer in east and south Asian populations, however, a pooled analysis of a number of 
studies found that risk was higher among carriers of the G/R72 allele.151-153 
The collection of these findings does not present a very clear picture, although it is possible p53 
plays variable roles in the tumorigenesis of different cancer types. Moreover, some have argued 
that such studies have been biased by limitations of study designs or ascertainment of genotypes, 
resulting in spurious associations or excess risk attributed to a specific allele.153,154 
The growing appreciation for the breadth of the roles and interactions of p53 has prompted studies 
to determine its targets in the genome through the determination of and search for p53 response 
elements (REs). p53 REs are sequences that act as binding targets for p53 in the setting of 
transcriptional control and they can vary in affinity, number, and positioning with respect to a gene 
under p53 transcriptional control and its promoter region. In addition to characteristics of the p53 
REs, numerous cofactors influence whether p53 will bind a given RE and if activation of 
transcription will take place.155 The study of structural interactions in the binding of p53 to DNA 
are complex and various models have emerged, potentially reflecting the extensive diversity in 
pathways and interactions in which p53 engages. Many sequences have been validated and are 
considered canonical p53 REs while genome-wide analyses have suggested that many more 





sites” serving as p53 binding sites in a similar manner to low-affinity canonical 20-base RE 
sequences has also significantly expanded the number of potential targets.158,159  
The ability and affinity of p53 binding to its REs can be altered by mutations in p53 resulting in 
various downstream effects.160 The same can also be said for mutations in the RE sequences 
themselves with numerous SNPs shown to disrupt functional p53 REs. Among these, a mutation 
in the promoter region of Toll-like receptor (TLR) 8 of the innate immune system has emerged as 
a SNP of interest.161,162 
p53, Toll-like Receptor 8, and the Innate Immune Response 
The Toll-like receptors (TLRs) are a family of microbial sensors involved in the innate immune 
system’s non-specific identification of pathogens via recognition of pathogen-associated 
molecular patterns. TLRs are transmembrane proteins located either at the cell surface or in 
intracellular endosomes and contain a sensory extracellular or luminal domain and an intracellular 
signaling domain. The members of the TLR family act as sensors for different microbial 
components and types of pathogens, including both bacteria and viruses, and initiate different 
pathways and responses upon stimulation.94,163 Additional roles of TLRs have been identified in 
other normal cellular processes, including cell differentiation and survival, as well as disease, 
including autoimmune disorders and cancer.164-166 
The TLR-dependent innate immune response has been described as having been thought of as 
“hard-wired” with gene induction almost exclusively mediated by interactions of TLRs with their 
respective stimuli, however, more recent studies have challenged this view with findings indicating 





TLR8 is an intracellular sensor of single-stranded viral RNA and induces production of antiviral 
interferons upon stimulation.94,171 The SNP rs3761624, featuring either an adenosine or guanosine 
base, is located in the promoter of TLR8 within a p53 RE and determines the binding affinity of 
p53 for this site.161,162 rs3761624 has been observed to be in perfect linkage disequilibrium with 
rs3764880, a nearby SNP in exon 1 of TLR8 characterized by a guanosine base replacing an 
adenosine base, which is more readily available in SNP panels and has received more attention in 
the literature.172 The G-allele of rs3764880 has previously been associated with slower progression 
of HIV in studies of mostly white and mostly east African participants but also with higher peak 
HIV viral load in a study of a Kenyan perinatal HIV cohort173-175 while the A-allele has been 
associated with reduced susceptibility to tuberculosis.176-178 TLR8 is encoded by a gene located on 
the X chromosome, meaning effects may be modified by sex, such as via X-inactivation in 
women.177 According to 1000Genomes, frequencies of the A allele of rs3764880 are 73% in white 
European, 71% in African, 19% in east Asian, and 42% in south Asian ancestral populations with 
nearly identical frequencies for the A allele of rs3761624.179,180 
Germline genetic variants in TP53 and TLR8 may individually or jointly influence risk of 
oncogenic infection and cancer in PLWHA through their effects on the p53-immune response 
signaling axis. It has been established that PWLHA are at elevated risk for infection-related 
cancers compared to the general population and additional non-HIV deficits in the immune 
response may confer additional risk.76 
The effect of TP53 SNP rs1042522 on its ability and affinity to bind to its REs has received little 
attention. One study assessed the effect of this SNP on p53 interaction with NF-ĸB, another major 
transcription factor, and transactivation of genes involved in immunity inflammation and found 





stimulation with lipopolysaccharide, a component of many bacterial cell walls.181 The findings 
from this study suggest that rs1042522 likely does influence the affinity of p53 for some REs. It 
is not known how rs1042522 influences p53 binding with the RE in the promoter of TLR8 in the 
presence or absence of rs3764880, but it is likely that there is modification of the binding affinity 
by both SNPs.  
The primary objective of this study is to assess the main and joint effects of rs1042522 and 
rs3764880 on incidence of all cancers, ADCs, NADCs, and infection-related cancers. Based on 
prior findings in studies of these SNPs as well as preliminary analysis of their effects on risk of 
AIDS following HIV seroconversion, we hypothesize that the G/R72 allele of TP53 and A-allele 
of TLR8 act synergistically to reduce risk of cancer in a cohort of HIV-positive men. The findings 
of this study could potentially aid in stratifying PLWHA by risk of cancer and guiding screening 




This study was conducted in a subset of participants of the Multicenter AIDS Cohort Study 
(MACS). The MACS is an ongoing prospective cohort study of HIV-infected and HIV-uninfected 
men which began with an initial recruitment of participants in Baltimore, Maryland; Chicago, 
Illinois; Los Angeles, California; and Pittsburgh, Pennsylvania from April 1984 through March 
1985. Subsequent waves of enrollment emphasized recruitment of minority participants and took 
place from April 1987 through September 1991 and October 2001 through August 2003. More 





therapies.182-184 The MACS was approved by the Institutional Review Boards at all study sites and 
all participants provided informed consent.  
Participants attended study visits by protocol approximately every six months and underwent 
physical examination, blood sample collection, neuropsychological evaluation, and questionnaires 
assessing medical history, behavior, quality of life, depression, activities of daily living, and 
medication use at each visit. Aliquots of blood samples were used to assay biomarkers of disease, 
including CD4+ cell count and HIV viral load, and other biological measures of immediate 
interest.184 Blood samples were also processed and aliquoted and specimens were kept locally for 
site-specific assays or sent to a central repository to be made available to investigators for future 
research. AIDS and non-AIDS diagnoses were ascertained by participant self-report and 
subsequent confirmatory medical record review or from other sources, such as death certificates 
as well as cancer and tuberculosis registries.183,185 
This study included participants enrolled in the first three waves with available SNP data and who 
contributed person-time under observation while HIV-positive. These participants were selected 
to explore the association of host genetics on HIV susceptibility and progression. 
Outcomes of Interest 
The primary outcome of interest in this study was incident cancer. Cancer diagnoses and dates of 
diagnosis were obtained by participant self-report at study visits with subsequent confirmation via 
medical record review or captured using state cancer registry data or death certificates.182 Cancer 
site and histology were documented using National Cancer Institute Surveillance, Epidemiology, 
and End Results Program (SEER) cancer site recodes for the International Classification for 





documented by state cancer registries and are not coded by SEER, were not considered in this 
analysis. 
Multiple classifications of cancer were considered as outcomes in this study, namely any cancer, 
ADCs, NADCs, and infection-related cancers. The outcome of any cancer was defined as the first 
occurrence of diagnosis of cancer in any SEER-defined site. ADCs were defined as the first 
occurrence of diagnosis of NHL, either nodal (SEER cancer site code: 33041) or extranodal 
(33042), or KS (36020). NADCs were defined as the first occurrence of diagnosis of cancer in a 
SEER-defined site not included in the definition of ADC, specifically any SEER code other than 
codes 33041, 33042, and 36020. Lastly, infection-related cancers were defined as the first 
occurrence of diagnosis of cancer in any of the following sites: oral cavity and pharynx, including 
lip (20010), tongue (20020), salivary gland (20030), floor of mouth (20040), gum and other mouth 
(20050), nasopharynx (20060), tonsil (20070), oropharynx (20080), hypopharynx (20090), and 
other oral cavity and pharynx (20100); stomach (21020); anus, anal canal and anorectum (21060); 
liver (21071), larynx (22020), lung and bronchus (22030); Hodgkin lymphoma, either nodal 
(33011) or extranodal (33012); NHL, either nodal (33041) or extranodal (33042); or KS (36020). 
Participants were able to contribute events to multiple cancer classifications and were not censored 
at time of diagnosis of a cancer that was not included in a particular outcome definition. As a result, 
a cancer diagnosis could contribute an event to one analysis but not another, even if it satisfied the 
outcome definition, if it was a participant’s second cancer diagnosis. Participants who experienced 
multiple events of the same cancer classification only contributed the first diagnosis as an event to 
analysis. 
Events were included in the analysis if they occurred while participants were under or within two 





following a participant’s most recent preceding study visit were excluded from consideration and 
participants were censored at the date of the most recent study visit preceding the diagnosis. 
Participants who did not experience an event were censored at the date of their most recent study 
visit. Remaining ongoing participant follow-up was administratively censored on December 31, 
2013 to allow for delays in ascertainment of new cancer cases. 
Exposures, Covariates of Interest 
The exposures of interest in this study were the SNPs rs1042522 in TP53 and rs3764880 in TLR8. 
Specimens stored in the MACS central repository were used to run SNP panels to provide 
investigators with genetic data for the study of effects of polymorphisms on a variety of outcomes. 
Genotypes for SNPs rs1042522 and rs3764880 were obtained from data generated by this effort 
in three separate initiatives, which included the use of TaqMan and Illumina-based genotyping 
assays and standard quality control measures. rs3764880 has been reported to be in perfect linkage 
disequilibrium with rs3761624,172 the SNP located in the p53 RE of the TLR8 promoter, and was 
used as a surrogate for the latter. rs1042522 genotypes, assessed in one genetic testing initiative, 
were determined only for a subset of participants who were evaluated for rs3764880, which was 
assessed in three genetic testing initiatives in the MACS. The possible genotypes at rs1042522 
were CC, CG, and GG. Since participants of the MACS are exclusively men and the gene encoding 
TLR8 is located on the X chromosome, participants only had one copy of TLR8 and one allele at 
rs3764880, thus, the possible genotypes at rs3764880 were G* and A*. SNP genotype data were 
linked to data collected at study visits as well as data on cancer diagnoses and were assessed for 
individual main effects of the TP53 SNP rs1042522 (GG vs. CG/CC genotype) and the TLR8 SNP 





rs1042522 GG and rs3764880 A* genotypes. The joint effect was modeled using an interaction 
term of the two hypothesized protective genotypes. 
Covariates of interest were collected at study visits and consisted of demographic data, including 
age and self-reported race; lifestyle and behavioral characteristics, including body mass index 
(BMI; kg/m2), current smoking status (never, current, or former), pack-year smoking history since 
last visit, cumulative lifetime pack-year smoking history, and alcohol consumption in terms of 
number of drinks consumed per week; and measures of HIV and its treatments, including CD4+ 
cell count (cells/mm3), plasma HIV viral load (copies/mm3), and current antiretroviral therapy 
(none, monotherapy, non-HAART combination therapy, or HAART). Antiretroviral therapy was 
defined as HAART based on DHHS/Kaiser Panel guidelines as three or more antiretroviral drugs 
consisting of one or more PIs, or one NNRTI, or one nucleoside or nucleotide reverse transcriptase 
inhibitor, or an integrase inhibitor, or an entry inhibitor (including fusion inhibitors).184 Finally, 
treatment eras were also considered, including the pre-HAART (1984 through 1995) vs. HAART 
(1996 through end of follow-up) eras as well as the pre-HAART vs. early HAART (1996-2001) 
vs. modern HAART (2002 through end of follow-up) periods. 
TP53 SNP rs1042522, TLR8 SNP rs3764880, and self-reported race were treated as fixed variables 
while age at visit, BMI, smoking status, pack-year smoking history since last visit, cumulative 
lifetime pack-year smoking history, alcohol consumption, injection drug use status, CD4+ cell 
count, HIV viral load, and antiretroviral therapy at time of visit were treated as time-varying 
variables. Body mass index, smoking status, pack-year smoking history since last visit, cumulative 
lifetime pack-year smoking history, alcohol consumption, injection drug use status, CD4+ cell 





more etiologically relevant measures of these variables and reduce the potential for reverse 
causality in covariate-exposure and covariate-outcome relationships. 
Missing data for exposures and covariates of interest were addressed using multiple methods. 
Missing data for time-varying covariates were imputed using a last observation carried forward 
approach. Observations were carried forward for up to four visits, corresponding to two years. The 
assumption of this approach was that true values for these covariates were stable and adequately 
captured by the last non-missing observation carried forward. Missing values for antiretroviral 
therapy remaining in the first ten scheduled MACS study visits corresponding to the first five years 
of the study (1984-1989) were imputed as participants not receiving antiretroviral therapy given 
that the first effective treatment was not approved until 1987 and participants with missing data in 
the two years following this date were assumed to have not yet initiated treatment. Similarly, 
remaining missing values of HAART for study visits preceding 1996 were imputed as not 
receiving HAART since such regimens were not available until this year. Missing values of 
antiretroviral therapy and HAART at study visits that preceded participants’ HIV diagnoses were 
imputed as not receiving therapy or HAART with the assumption that they were not receiving 
prophylactic antiretroviral therapy. 
For the purposes of analysis, covariates were categorized as follows: age at visit (less than 35, 35-
45, 45-55, or over 55), race (white, black, Hispanic, or other), CD4+ cell count (less than 200, 200-
350, 350-500, or over 500 cells/mm3), HIV viral load (less than 1000 or 1000 or greater 
copies/mm3), cumulative pack-year smoking history (less than 10, 10-20, 20-30, or over 30), 
alcohol consumption in terms of number of drinks consumed per week (none, 1-3, 4-13, or over 
13), and BMI (less than 25, 25-30, or greater than 30). In addition, the HAART and HIV viral load 





HAART and but not virally suppressed (HIV viral load of 1000 copies/mm3 or greater), and 
receiving HAART and virally suppressed (HIV viral load under 1000 copies/mm3). During 
analysis, covariates were collapsed into fewer groups if categories showed similar associations 
with outcomes. 
Statistical Analysis 
Demographic and baseline characteristics were described as ascertained at participants’ baseline 
visit. Participants contributed person-time to this analysis only while HIV-infected, meaning those 
who were HIV-infected at enrollment began contributing person-time at this visit while those who 
were HIV-uninfected at enrollment did not contribute person-time until seroconversion. Person-
time contribution ended at the time of an incident event, time of censoring, or death. Person-time 
contribution did not end if a participant was diagnosed with a cancer not included in the outcome 
definition. 
Cancer incidence rates (IR) were calculated by dividing the number of events observed by the 
person-time of follow-up accrued and exact Poisson regression was used to estimate incidence rate 
ratios (IRR). The exact method was used to compute confidence intervals due to small numbers of 
events in combinations of strata of exposures and covariates of interest which make maximum-
likelihood estimate-based Poisson regression unsuitable.  
Univariable exact Poisson regression was used to estimate crude IRRs for the SNPs and covariates 
of interest. Covariates were then individually modeled with main and joint SNP effects to assess 
influence of adjusting for each covariate on SNP estimates for consideration during multivariable 
modeling. Multivariable exact Poisson regression was conducted to estimate adjusted IRRs for 





was forced into the multivariable model for each outcome. Additional covariates included in the 
final multivariable model were determined based on available knowledge of associations with 
outcomes and on the extent to which covariates altered SNP effects when modeled individually 




Our study population included 760 MACS participants with available SNP data and study visit 
data. At enrollment, 318 participants (41.8%) were HIV-infected and 442 participants (58.2%) 
were HIV-uninfected. Among participants who were HIV-uninfected at enrollment, the median 
time from enrollment to seroconversion was 2.5 years (IQR: 1.0-6.1) and median age at 
seroconversion was 35.1 (IQR: 29.6-41.6). Participants were predominantly enrolled in the first 
wave of MACS enrollment, with 626 participants (82.4%) enrolled in this period. Participants 
contributed a median of 9.3 years (IQR: 4.7-21.3) years of follow-up while HIV-infected. Ten 
participants contributed no follow-up while HIV-positive and were not included in time-to-event 
analysis. 
All 760 participants had data available for TLR8 SNP rs3764880, 222 (29.2%) of whom had the G 
allele and 538 (70.8%) of whom had the A allele at this site. 263 participants (34.6%) had data 
available for TP53 SNP rs1042522, 115 (43.7%) of whom had genotype CC, 110 (41.8%) with 
genotype CG, and 38 (14.4%) with genotype GG at this site. Among participants with data for the 





addition, all participants in this subset were HIV-positive at enrollment and contributed a median 
8.9 years of follow-up (IRQ: 4.9-25.5). 
Baseline characteristics 
Baseline characteristics obtained at enrollment visit were relatively evenly distributed when 
participants were stratified by TLR8 SNP allele (Table 1). Differences were observed in smoking 
status, with more current smokers among participants with the G allele, and HIV status, with more 
HIV-positive participants among participants with the A allele. 
However, stratifying by TP53 SNP genotype revealed several differences in baseline 
characteristics between the groups (Table 2). The distributions of self-reported race varied across 
genotypes, with clear trends in proportions of participants reporting white, black, and 
Latin/Hispanic ancestry in each group. Moreover, differences in distributions were observed across 
TP53 SNP genotypes in most covariates considered, some of which may be related to the 
differential allele and genotype frequencies observed by race. These included smoking history, 
cumulative pack-years of smoking history, and alcohol consumption. 
The distributions of self-reported race by TLR8 SNP status were similar and allele frequencies 
were relatively consistent across white, black and Latin/Hispanic participants. In contrast, allele 
frequencies of the TP53 SNP varied by race, with the lowest frequencies of the protective G allele 
participants of Latin/Hispanic, other, and white groups while those with black ancestry had the 
highest frequency of this allele (Table 3). 
Cancer Diagnoses 
One hundred thirty-three first diagnoses of any cancer were observed during 8,734.0 years of 





100 person-years. Cancer diagnoses occurred a median of 6.0 years (IQR: 4.6-10.2) after 
enrollment. The most common diagnoses were KS, NHL, and prostate cancer with ADCs (KS and 
NHL) accounting for two thirds of first cancer diagnoses (Table 3). The cumulative incidence 
curve of first diagnosis of any cancer shows greatest risk in the period of four to eight years after 
enrollment, followed by a sustained risk for the rest of follow-up (Figure 1). 
In analysis of ADCs alone, 92 first diagnoses were observed during 8,905.9 years of follow-up 
time, resulting in an incidence rate of 1.02 (95% CI: 0.83-1.25) first ADC diagnoses per 100 
person-years. Diagnoses of ADC occurred a median of 6.34 years (IQR: 4.2-7.6) years after 
enrollment. KS accounted for 80% of diagnoses, followed by extranodal and nodal NHL, 
respectively (Table 3). The cumulative incidence curve of first diagnosis of ADC shows greatest 
risk between four and eight years after enrollment with, with risk dissipating by twelve years and 
plateauing for the remainder of follow-up time (Figure 2).  
In analysis of NADCs alone, 49 first diagnoses were observed during 8,949.7 years of follow-up 
time, resulting in an incidence rate of 0.50 (95% CI: 0.38-0.67) first NADC diagnoses per 100 
person-years. Diagnoses of NADC occurred a median of 13.7 years (IQR: 6.0-18.3) after 
enrollment. The most common diagnoses were prostate cancer, cancers of the anus, anal canal and 
anorectum, and melanoma, respectively (Table 3). The cumulative incidence curve of first 
diagnosis of NADC suggests a relatively constant risk over the duration of follow-up time (Figure 
3). 
Finally, in analysis of infection-related cancers, 110 first diagnoses were observed during 8,847.6 
years of follow-up, resulting in an incidence rate of 1.20 (95% CI: 0.99-1.45) first diagnoses of 
infection-related cancer per 100 person-years. Diagnoses of infection-related cancers occurred a 





cancers, followed by cancers of the anus, anal canal and anorectum (Table 3). The cumulative 
incidence curve of first infection-related cancer shows a similar trend to the curve for ADCs in the 
first 12 years of follow-up but does not plateau as infection-related NADCs continue to occur later 
in follow-up (Figure 4). 
Univariable Analysis 
The incidence of cancer of any type decreased over time, with a substantial reduction in risk in the 
HAART era observed compared to the pre-HAART era. Within the HAART era, risk of cancer 
overall appeared to remain relatively consistent, with no further reduction in risk in the modern 
compared to the early HAART era. Protective effects were observed for both SNPs, with 41% 
(IRR: 0.59, 95% CI: 0.15-1.63) and 17% (IRR: 0.83, 95% CI: 0.57-1.23) reduction in incidence of 
any cancer in participants with the protective genotypes of the TP53 and TLR8 SNPs, respectively 
(Table 4). Among covariates of interest, age did not show consistent association with cancer while 
non-white participants were found to have lower cancer incidence than white participants. Among 
measures of disease severity and therapy, higher CD4+ cell count and treatment with HAART 
were found to be protective against cancer diagnosis of any type. Risk was higher among 
participants with HIV viral load of 1000 copies/mm3 or greater compared to those with lower HIV 
viral load, but this difference dissipated among those receiving HAART. Lifestyle factors; 
including smoking status, cumulative pack-year smoking, and alcohol consumption; showed 
inconsistent associations with cancer across categories. 
Significant trends over calendar time were also observed for ADC, with an even greater reduction 
in risk observed for ADCs in the HAART era compared to the pre-HAART era than was observed 
for all cancers. Within the HAART era, incidence of ADCs was further reduced in the modern 





respect to incidence of ADCs, with a 41% (IRR: 0.59, 95% CI: 0.11-1.91) reduction in incidence 
for participants with the protective TP53 genotype and a 17% (IRR: 0.83, 95% CI: 0.53-1.33) 
reduction in incidence in participants with the protective TLR8 genotype. Incidence of ADCs was 
found to decrease with increasing age, potentially due to lower engagement in high-risk behaviors 
among older participants, and risk was lower among black and Latin/Hispanic participants 
compared to white participants. Higher CD4+ cell count was found to be protective while higher 
HIV viral load was associated with ADC. No events were observed among participants receiving 
HAART, regardless of viral load. Participants consuming any alcohol and those who were 
underweight or normal per BMI were found to be at increased risk of ADCs, although confidence 
intervals included the null, while smoking status and cumulative pack-year history showed 
inconsistent trends, respectively (Table 5). 
In contrast with all cancers and ADC, the incidence of NADC increased, with greater than two-
fold higher incidence in the HAART than the pre-HAART era. Both SNPs were found to be 
protective, with 54% (IRR: 0.46, 95% CI: 0.01-3.13) and 21% (IRR: 0.79, 95% CI: 0.42-1.54) 
reductions in participants with the protective TP53 and TLR8 SNPs, respectively. Furthermore, 
unlike the results for all cancers and ADCs, older age was strongly associated with risk of NADCs. 
Black participants were at slightly lower risk for NADCs than white participants while no NADCs 
were observed for participants of Latin/Hispanic or other race. Higher CD4+ cell count was 
protective against NADC, however, confidence intervals for most estimates included the null, and 
HIV viral load showed no association with risk of NADCs. Incidence of NADCs was higher among 
participants treated with HAART, most likely due to prolonged survival allowing sufficient time 
for the development of cancers with longer latency. Interestingly, BMI showed reduced risk among 





normal participants, however, confidence intervals for both estimates included the null. While 
smoking status showed inconsistent associations across categories, higher cumulative pack-years 
of smoking was associated with increased risk of NADC. Surprisingly, alcohol consumption did 
not show any association with NADC (Table 6). 
Lastly, infection-related cancers also decreased over time, with a reduction in risk from pre-
HAART, through early HAART, and into the modern HAART era. The effects of SNPs were again 
found to be protective, with 53% (IRR: 0.47, 95% CI: 0.09-1.48) and 13% (IRR: 0.87, 95% CI: 
0.57-1.35) reductions in incidence in participants carrying the protective TP53 and TLR8 SNP 
genotypes, respectively, compared to non-carriers. Older age was associated with an increasingly 
protective effect, although this may again potentially be due to reduced high-risk behaviors in these 
participants. Incidence of infection-related cancers was lower among non-white participants 
compared to white participants. Increasing categories of CD4+ cell count showed an increasingly 
protective effect. Among participants receiving HAART, those with high viral load were at higher 
risk than those with low viral load, but at substantially lower risk than those not receiving HAART. 
Among lifestyle factors, incidence of infection-related cancer was lower among overweight or 
obese participants by BMI and higher in participants consuming any alcohol, although confidence 
intervals included the null. Smoking status and cumulative pack-years smoking were not 
associated with risk of infection-related cancer (Table 7). 
The SNPs of interest both showed expected effects, with the GG genotype of TP53 SNP rs1042522 
and, to a lesser extent, A* genotype of TLR8 SNP rs3764880 both found to be protective for all 








For the multivariable analysis, we began by fitting a model to estimate the main and joint effects 
of the TP53 and TLR8 SNPs on the incidence of any cancer adjusted for race, BMI, smoking 
history, CD+4 cell count, and a composite measure of HIV treatment (HAART) and treatment 
effectiveness (HIV viral load). The main effects of both SNPs remained protective against cancer 
diagnosis of any type, with reduction in incidence of 35% (IRR: 0.65, 95% CI: 0.01-5.74) and 8% 
(IRR: 0.92, 95% CI: 0.33-2.93) for carriers of the protective TP53 GG and TLR8 A* genotypes, 
respectively, compared to non-carriers. These were slightly attenuated compared to effects 
observed in univariable analysis. The interaction between the two SNPs was found to be 
additionally protective, indicating a joint effect of the two SNPs. Participants with protective 
genotypes at both SNPs appeared to be at lower risk of cancer with the interaction of the two SNPs 
indicating a half-fold reduction in risk (IRR: 0.46, 95% CI: 0.01-42.71). Confidence intervals for 
all SNP effects, however, contained the null (Table 8). 
Among covariates included, CD4+ cell count above 350 cells/mm3 and HAART irrespective of 
viral load were found to protect against cancer. Smoking and overweight/obese BMI were also 
consistent with a protective effect, although these may be reflections of disease severity or overall 
health rather than true effects of these exposures on the outcome. Confidence intervals for effects 
of all covariates contained the null value except for that of CD4+ cell count (Table 8).  
Multivariable analysis produced a similar model estimating main and joint effects of the TP53 and 
TLR8 SNPs on incidence of ADC with the same adjustment set of race, BMI, smoking history, 
CD+4 cell count, and the composite of HAART status and HIV viral load. The protective effect 
observed for the TP53 SNP GG genotype in univariable analysis was entirely adjusted away, 





TLR8 SNP A* genotype remained virtually unchanged, with a 16% reduction in incidence of ADC 
in carriers compared to non-carriers. The interaction between the two SNPs was found to be 
additionally protective, again indicating a joint effect of the SNPs on incidence of ADCs. 
Participants with protective genotypes at both SNPs were at lower risk for ADCs, with a 53% 
reduction (IRR: 0.47, 95% CI: 0.01-48.55) in incidence compared to participants not carrying both 
protective genotypes. The null association of TP53 and weak protective effect of TLR8 with a 
strong interaction indicate a protective effect of each SNP only in the presence of the other SNP. 
Confidence intervals for SNPs again all contained the null as was the case for the outcome of any 
cancer (Table 9). 
Among covariates included, CD4+ cell count above 350 cells/mm3 was protective against ADCs, 
albeit to a lesser extent than the effect observed for any cancer, but HAART alone was not. Among 
participants receiving HAART, those with viral load above 1000 copies/mm3 were at slightly 
higher risk of ADC than those not on HAART while those with viral load below this threshold 
were at substantially lower risk. Smoking and overweight/obese BMI were found to protect against 
ADCs to a greater extent than observed for any cancer, again potentially reflecting disease severity 
or overall health of participants. Confidence intervals of covariate effects all contained the null 
value (Table 9). 
Multivariable analysis was unable to produce a model estimating adjusted main and joint effects 
of SNPs on incidence of NADCs. Only one NADC was observed among participants with the 
protective genotypes for both SNPs, resulting in adjusted models including the interaction term 
failing to converge. Consequently, no adjusted SNP effects are reported for NADCs. 
Finally, multivariable analysis produced a model estimating main and joint effects of SNPs on 





consumption, CD4+ cell count, and the composite of HAART status and HIV viral load. The 
protective effects for both SNPs observed in univariable analysis were attenuated following 
adjustment, resulting in a slightly protective effect for the TP53 SNP (IRR: 0.86, 95% CI: 0.02-
8.00) and a null effect for the TLR8 SNP (IRR: 1.01, 95% CI: 0.33-3.69) in the final multivariable 
model. Incidence of infection-related cancer was reduced by 14% in participants with the TP53 
GG genotype compared to those carrying other genotypes while there was no difference in 
incidence based on TLR8 SNP status. Participants with protective genotypes at both SNPs were 
found to be at lower risk, with a 60% (IRR: 0.40, 95% CI: 0.01-39.37) reduction in incidence 
compared to participants not carrying both protective genotypes. Similar to ADCs, the observation 
of weak main effects and stronger joint effect indicate SNP effects only in the presence of each 
other. Confidence intervals for SNP effects all contained the null (Table 10). 
Similar to associations observed in the analysis of ADCs, CD4+ cell count over 350 cells/mm3 
was found to be protective while HAART alone was not. A protective effect of HAART was only 
observed in participants with viral load below 1,000 copies/mm3 while participants with viral load 
above this threshold were at slightly increased risk compared to those not receiving HAART. 
Overweight/obese BMI and smoking were also found to be protective against infection-related 
cancers, again potentially reflecting disease severity or overall health, while greater alcohol 
consumption was found to increase risk. Confidence intervals for all covariate effects, with the 









Significant attention has previously been devoted to the effect of the TP53 SNP rs1042522 on risk 
of cancer,135-154 however, to our knowledge this is the first study to assess its effect in combination 
with TLR8 with respect to cancer. While p53 is best known for its tumor suppressor function, an 
increasing appreciation for the role of p53 in immune function has emerged, which may include a 
pathway through a p53 response element in TLR8, with binding subject to the TLR8 SNP assessed 
in this study.161-162 Accordingly, the significance of studying these SNPs as a pair is the potential 
for differential immune response by SNP status and a synergistic effect of the protective genotypes, 
which may identify participants at higher risk for development of cancer or may improve 
understanding of the etiology of certain cancers in PLWHA. 
The results of this study are consistent with the hypothesis of a synergistic protective effect of 
SNPs in TP53 and TLR8 on the incidence of multiple classifications of cancer in MACS 
participants. The interaction between SNPs was found to be protective in multivariable models for 
any cancer, ADCs, and infection-related cancers – with strongest effect observed for the latter – 
while main effects of SNPs varied by outcome, with the TP53 GG genotype shown to be most 
protective for incidence of any cancer and to have a null effect for ADCs while the TLR8 A* 
genotype was most protective against ADCs and showed a null effect for infection-related cancers. 
Statistical interactions, representing the joint effect of SNPs, were observed to be protective in 
multivariable models for any cancer, ADCs, and infection-related cancers. These results support 
the hypothesized role of the p53-TLR8 axis in the immune response on the development of these 
cancers in men with HIV/AIDS. 
Allele frequencies of TP53 variants based on self-reported race differed in this study from those 





allele among white northern European samples compared to samples taken from African 
populations and an inverse relationship between C/P72 allele frequency and latitude in east Asia, 
however, this study observed a higher frequency of the C/P72 allele among white and 
Latin/Hispanic participants than black participants.130-132 There are several potential explanations 
for these observations, including relatively small sample size, discrepancy between genetic 
ancestry and self-reported race in the study sample, or possibly some sort of selection. Future 
avenues of research could address some of these potential explanations. Allele frequencies 
observed for TLR8 SNP rs3764880 were concordant with those reported by 1000Genomes.179,180 
SNP effects observed were similar across outcomes of any cancer, ADCs, and infection-related 
cancers, most likely due to the composition of cancers within these classifications observed during 
follow-up. ADCs were the predominant type of cancer observed in this study, accounting for 67% 
of events in the any cancer outcome and 85% of infection-related cancers. As a result, associations 
between SNPs and ADCs likely contributed significantly to effects observed for the other outcome 
classifications which included ADCs and may explain why final adjusted models were similar. 
Although this study did not have enough events to assess additional cancer classifications, it may 
be of interest to conduct analyses excluding ADCs to characterize the effects of these SNPs on 
general cancer development in both HIV and non-HIV populations. 
Unfortunately, adjusted main and joint SNP effects on incidence of NADC could not be estimated 
in multivariable analysis. Only one NADC was observed among participants with protective 
genotypes at both SNPs and multivariable exact Poisson regression modeling failed when the SNP 
interaction term was included. While the unadjusted SNP effects for NADCs were similar to those 
observed for other cancers, the unadjusted effects of some other covariates differed. In the event 





of SNP effects from those observed for other cancer outcomes due to potential differences in how 
inclusion of covariates in a given model could influence estimated SNP effects. 
Effects observed for other participant characteristics were largely consistent with previously 
reported associations,38,42-49,86-90 with the exception of smoking. Smoking lagged by two years; 
categorized as never, ≤30 pack-year history, and >30 pack-year history; was associated with lower 
cancer risk in all multivariable models, with greater protection among participants with more 
extensive exposure. In this case, smoking may represent better overall health or less severe HIV 
disease, although this is not clear. Smoking showed a null or adverse effect on risk in univariable 
model and given previously identified effects of rs1042522 on apoptosis, which can occur as a 
consequence of cigarette smoke-induced damage,127,128,187,188 it is possible that this SNP is also 
associated with smoking or its effects which was not fully accounted for in our modeling. 
Similarly, participants who were overweight or obese by BMI were found to be at reduced risk 
compared to normal or underweight participants. This association may be explained by low BMI 
acting as a marker of disease severity through disease-related wasting, representing a high-risk 
group for cancer. Direct measures of disease severity and treatment, CD4+ cell count and a 
composite of HAART and viral load, both described associations of adequately treated and less 
severe disease with reduced risk of cancer, reiterating the importance of immune function in the 
development of cancer among PLWHA. 
There were a number of limitations in this study which will be addressed in further work and 
analyses using these data, most notably using an all-male sample, missing data, and potentially 
inadequate adjustment for genetic ancestry. This analysis was conducted on data obtained from 
participants of the MACS, a study which exclusively enrolled male participants. Given differential 





among PLWHA and possible that the effects of the SNPs of interest may be influenced or modified 
by sex – something that could not be assessed in this study population. This study also could not 
assess several cancers only observed in women, most notably cervical cancer, which is an ADC. 
To address this limitation, further work on this analysis will incorporate data from the Women’s 
Interagency HIV Study (WIHS). The WIHS is an ongoing prospective cohort study enrolling HIV-
positive women which began with an initial recruitment of participants at six sites from October 
1994 to November 1995 with multiple subsequent waves of enrollment at variable numbers of 
sites.189 The conduct of and data collected by the WIHS study are similar to the MACS in terms 
of exposures, covariates, and outcomes of interest in this study, allowing for a combined analysis. 
There are, however, notable differences between the participants of the two studies. Some 
important differences are racial composition; with a greater proportion of black participants in the 
WIHS; and method of HIV transmission, with more exposures through IDU than sexual 
transmission in the WIHS than the MACS. These differences will likely require additional 
considerations in the analysis. 
This study was also limited by missing data in exposures and covariates of interest, which 
substantially reduced analytic sample size. Out of 760 participants included in analysis, all 
participants were assed for the TLR8 SNP in three separate genetic testing initiatives while 497 
(65%) were not tested for the TP53 SNP in any of these three studies, resulting in their exclusion 
from univariable and multivariable models including terms for this SNP.  
Baseline characteristics among those missing TP53 data varied compared to those observed for 
participants with TP53 data, most notably in HIV status at enrollment. Among participants missing 
data for this SNP, 89% were HIV-uninfected at enrollment while there were no HIV-uninfected 





data resulted in an analytic sample entirely composed of participants who were HIV-infected at 
baseline. This study did not use a time-to-event analysis approach but rather one that treats person-
time under observation equally, so the lack of observation of participants at and early after 
seroconversion does not threaten the validity of the analytic methods used. 
Future work on this analysis will employ SNP imputation informed by 1000 Genomes or TopMed 
reference panel data to improve sample size. The imputation of TP53 data will allow for inclusion 
of a substantial proportion of the study sample in analysis and the potential for subset analysis of 
participants who seroconverted under observation using time-to-event methods. This method of 
imputation would also be used to address any issues in missing SNP data that may arise in WIHS 
data. Furthermore, an ongoing genome-wide association study initiative will yield TP53 SNP data 
on a large sample of MACS participants, allowing for the examination of these SNPs for both 
HIV-infected and uninfected participants.  
Missing data in covariates is another limitation of this study which will be addressed in subsequent 
work. The study and results reported here largely used a last-observation-carried-forward 
imputation approach. In this approach, observations for missing time-varying covariates were 
carried forward for up to four visits representing two years. The strength of this approach is that 
the extent of missing data is reduced, however, it is also not without limitations. Among numerous 
limitations, this approach does not capture changes in covariates over time and makes no 
considerations about missing data mechanisms by assuming data are missing completely at 
random. 
Future work on this analysis will use a multiple imputation approach to address missing data. This 
will first include considerations of missing data mechanisms, in part determining whether multiple 





appropriate. The benefits of multiple imputation compared to the approach used in this study are 
numerous, with preservation of the underlying distribution of observed covariates after imputation, 
and incorporation of missing data mechanisms and imputation based on observed covariates where 
appropriate, the most notable advantages. 
Lastly, this study was limited by the method of adjustment for genetic ancestry. The study of 
genetic exposures requires adjustment for population stratification, a type of confounding in which 
cases and controls may have different underlying distributions of genetic ancestry. In this study, 
self-reported race was used to adjust for genetic ancestry, however, this was likely an inadequate, 
and in cases of misclassification inappropriate, means of adjustment. Future work will seek to 
improve adjustment for population stratification by using additional genetic data to compute 
genetic ancestry for each participant to be used to as the adjustment variable instead of self-
reported race. 
Upon addressing these limitations, this analysis will be able to examine differences in SNP effects 
by sex, address cancers which are only observed in women, and produce more precise estimates 
of SNP effects. Furthermore, the addition of WIHS data as well as SNP and covariate imputation 
will likely add sufficient events to enable multivariable modeling of adjusted SNP effects on 
incidence of NADCs and sensitivity analyses to assess the robustness of results, adding to the 
results reported here. Although it is unclear if an updated analysis incorporating these changes will 
estimate SNP effects that are statistically significant, it appears clear that these effects exist after 
adjustment for relevant covariates and that lack of statistical significance in the current study may 
be an issue of limited sample size. 
There are also potential limitations which cannot be readily assessed or addressed in this study. 





ascertainment of cancers in this study was based on participant self-report with confirmatory 
medical record review as well as review of death certificates, and in some states, linkage to state 
cancer registries. Follow-up was stopped several years prior to when this data analysis was 
performed to allow for delays in cancer reporting and ascertainment. The potential limitations in 
cancer ascertainment are not due to these methods specifically but rather biases that exist in cancer 
screening, including lead-time bias and length-time bias, in which time or timing of cancer 
diagnoses may have differed by disease or frequency of screening, respectively. 
Differential loss to follow-up was likely also an issue with participants with more advanced HIV 
disease missing study visits and being lost to follow-up. There were numerous cancer diagnoses 
recorded more than two years after participants’ last visits that were excluded with participants 
censored at last follow-up. These participants may have had advanced disease and the exclusion 
of these cancer cases may have resulted in underestimates of associations of measures of disease 
severity and cancer outcomes. In the event that these limitations did impact the results of this study, 
it is likely that they biased results towards the null. 
This study demonstrated a possible role for the p53-TLR8 axis of the immune response in the 
development of cancer in PLWHA, with participants carrying protective genotypes at both the 
TP53 and TLR8 SNPs at substantially reduced risk of cancer compared to those with neither 
protective genotype. The observation of this protective effect supports the hypothesis of higher 
affinity binding of p53 to its receptor element in TLR8 and subsequent transcription of TLR8, 
resulting in a more robust immune response to viral pathogens. 
The findings from this study identify relatively common SNPs with variable allele frequencies 
across ancestral populations which may help stratify PLWHA with respect to cancer risk. In spite 





for cancer compared to the general population. The introduction of HAART led to a significant 
reduction in ADCs, however, it is now well-established that PLWHA are also at higher risk for 
many NADCs than the general population. Among other cancer outcomes, this study specifically 
assessed the effects of SNPs that affect the immune response on the development of infection-
related cancers, which includes both ADCs and a number of NADCs. Treatment with HAART 
prolongs survival with life expectancy approaching that of the general population with adequate 
access to care and full adherence, however, most do not regain full immune function and PLWHA 
are likely to remain at elevated risk for infection-related cancers. Therefore, these findings may be 
used to inform further developments in screening strategies, chemoprevention, and other 















Tables and Figures 
Table 1: Baseline Characteristics (stratified by TLR8 genotype) 
Variable 
Median (IQR) or n (%) 
A* (N=538) G* (N=222) 
Age 
Median (IQR) 31.2 (26.8-36.5) 31.1 (26.9-35.8) 
<35 366 (68.0) 158 (71.2) 
35-44 138 (25.7) 56 (25.2) 
45-54 28 (5.2) 8 (3.6) 
55-64 4 (0.7) 0 (0.0) 
≥65 2 (0.4) 0 (0.0) 
Race 
White 446 (82.9) 176 (79.3) 
Black 68 (12.6) 28 (12.6) 
Latin/Hispanic 22 (4.1) 14 (6.3) 
Other 2 (0.4) 4 (1.8) 
TP53 genotype 
CC 84 (15.6) 31 (14.0) 
CG 84 (15.6) 26 (11.7) 
GG 25 (4.6) 13 (5.9) 
Missing 345 (64.2) 152 (68.5) 
BMI (kg/m2) 
Median (IQR) 23.0 (21.6-24.8) 22.5 (21.1-24.4) 
<25 406 (75.5) 174 (78.4) 
25-30 101 (18.8) 36 (16.2) 
>30 20 (3.7) 11 (5.0) 
Missing 11 (2.0) 1 (0.5) 
Alcohol consumption (drinks per week) 
0 24 (4.5) 17 (7.7) 
1-3 151 (28.1) 55 (24.8) 
4-13 244 (45.4) 101 (45.5) 
>13 99 (18.4) 46 (20.7) 
Missing 20 (3.7) 3 (1.4) 
Smoking status 
Never 205 (38.1) 73 (32.9) 
Former 97 (18.0) 35 (15.8) 
Current 228 (42.4) 114 (51.4) 
Missing 8 (1.5) 0 (0.0) 
Cumulative pack-years smoking history 
Median (IQR) 2.7 (0.0-19.5) 3.7 (0.0-20.8) 
<10.0 338 (62.8) 139 (62.6) 
10.0-19.9 68 (12.6) 27 (12.2) 
20.0-30.0 59 (11.0) 19 (8.6) 
>30 66 (12.3) 37 (16.7) 
Missing 7 (1.3) 0 (0.0) 
HIV-infected 
No 304 (56.5) 138 (62.2) 








Table 1: Baseline Characteristics (stratified by TLR8 genotype; 
continued) 
Variable 
Median (IQR) or n (%) 
A* (N=538) G* (N=222) 
CD4+ count (cells/mm3) 
Median (IQR) 771 (559-1022) 791 (573-1010) 
<200 4 (0.7) 4 (1.8) 
200-349 21 (3.9) 5 (2.3) 
350-500 66 (12.3) 25 (11.3) 
>500 431 (80.1) 186 (83.8) 
Missing 16 (3.0) 2 (0.9) 
Viral load (copies/mm3) 
Median (IQR) 0 (0-300) 0 (0-300) 
<1000 291 (54.1) 134 (60.4) 
≥1000 48 (8.9) 23 (10.4) 
Missing 199 (37.0) 65 (29.3) 
Abbreviations: BMI – body mass index, IQR – interquartile range; values reported 



































Table 2: Baseline Characteristics (stratified by TP53 genotype) 
Variable 
Median (IQR) or n (%) 
GG (N=115) GC (N=110) CC (N=38) Not Tested (N=497) 
Age 
Median (IQR) 31.1 (27.4-35.3) 33.0 (28.6-37.7) 32.2 (26.7-36.7) 30.8 (26.3-36.4) 
<35 85 (73.9) 69 (62.7) 27 (71.1) 343 (69.0) 
35-44 27 (23.5) 30 (27.3) 8 (21.1) 129 (26.0) 
45-54 2 (1.7) 10 (9.1) 2 (5.3) 22 (4.4) 
55-64 1 (0.9) 1 (0.9) 1 (2.6) 1 (0.2) 
≥65 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.4) 
Race 
White 98 (85.2) 80 (72.7) 14 (36.8) 430 (86.5) 
Black 6 (5.2) 23 (20.9) 24 (63.2) 43 (8.7) 
Latin/Hispanic 9 (7.8) 5 (4.5) 0 (0.0) 22 (4.4) 
Other 2 (1.7) 2 (1.8) 0 (0.0) 2 (0.4) 
TLR8 
G* genotype 31 (27.0) 26 (23.6) 13 (34.2) 152 (30.6) 
A* genotype 84 (73.0) 84 (76.4) 25 (65.8) 345 (69.4) 
BMI(kg/m2) 
Median (IQR) 22.8 (21.6-24.2) 23.0 (21.6-24.5) 23.2 (21.7-25.7) 22.9 (21.4-24.9) 
<25 97 (84.3) 88 (80.0) 26 (68.4) 369 (74.2) 
25-30 14 (12.2) 18 (16.4) 10 (26.3) 95 (19.1) 
>30 3 (2.6) 4 (3.6) 2 (5.3) 22 (4.4) 
Missing 1 (0.9) 0 (0.0) 0 (0.0) 11 (2.2) 
Alcohol consumption (drinks per week) 
0 5 (4.3) 9 (8.2) 5 (13.2) 22 (4.4) 
1-3 35 (30.4) 30 (27.3) 10 (26.3) 131 (26.4) 
4-13 50 (43.5) 50 (45.5) 11 (28.9) 234 (47.1) 
>13 21 (18.3) 20 (18.2) 10 (26.3) 94 (18.9) 
Missing 4 (3.5) 1 (0.9) 2 (5.3) 16 (3.2) 
History of smoking 
Never 40 (34.8) 38 (34.5) 16 (42.1) 184 (37.0) 
Former 19 (16.5) 22 (20.0) 7 (18.4) 84 (16.9) 
Current 55 (47.8) 50 (45.5) 15 (39.5) 222 (44.7) 
Missing 1 (0.9) 0 (0.0) 0 (0.0) 7 (1.4) 
Cumulative pack-years of smoking history 
Median (IQR) 3.4 (0.0-19.5) 3.5 (0.0-21.9) 0.5 (0.0-12.0) 3.2 (0.0-18.8) 
<10.0 72 (62.6) 66 (60.0) 28 (73.7) 311 (62.6) 
10.0-19.9 14 (12.2) 15 (13.6) 2 (5.3) 64 (12.9) 
20.0-30.0 10 (8.7) 14 (12.7) 5 (13.2) 49 (9.9) 
>30.0 18 (15.7) 15 (13.6) 3 (7.9) 67 (13.5) 
Missing 1 (0.9) 0 (0.0) 0 (0.0) 6 (1.2) 
HIV-infected 
No 0 (0.0) 0 (0.0) 0 (0.0) 442 (88.8) 









Table 2: Baseline Characteristics (stratified by TP53 genotype; continued) 
Variable 
Median (IQR) or n (%) 
GG (N=115) GC (N=110) CC (N=38) Not Tested (N=497) 
CD4+ count (cells/mm3) 
Median (IQR) 651 (512-889) 604 (467-810) 577 (407-814) 848 (642-1097) 
<200 2 (1.7) 3 (2.7) 2 (5.3) 1 (0.2) 
200-349 4 (3.5) 10 (9.1) 0 (0.0) 12 (2.4) 
350-500 18 (15.7) 23 (20.9) 12 (31.6) 38 (7.6) 
>500 86 (74.8) 73 (66.4) 24 (63.2) 434 (87.3) 
Missing 5 (4.3) 1 (0.9) 0 (0.0) 12 (2.4) 
Viral load (copies/mm3) 
Median (IQR) 27705 (8761-46935) 7440 (3763-27599) 20064 (4433-57680) 0 (0-40) 
<1000 1 (0.9) 1 (0.9) 1 (2.6) 422 (84.9) 
≥1000 15 (13.0) 16 (14.5) 8 (21.1) 32 (6.4) 
Missing 99 (86.1) 93 (84.5) 29 (76.3) 43 (8.7) 





































Table 3: TP53 and TLR8 Allele Frequencies by Race 








































































Count Percent Count Percent Count Percent Count Percent 
Floor of mouth 20040 1 0.75 - - 1 2.04 1 0.91 
Tonsil 20070 1 0.75 - - 1 2.04 1 0.91 
Esophagus 21010 1 0.75 - - 2 4.08 - - 
Hepatic flexure 21044 1 0.75 - - 1 2.04 - - 
Large intestine, NOS 24049 1 0.75 - - 1 2.04 - - 
Anus, anal canal and anorectum 21060 4 3.01 - - 5 10.20 5 4.55 
Liver 21071 3 2.26 - - 3 6.12 3 2.73 
Lung and bronchus 22030 3 2.26 - - 3 6.12 3 2.73 
Melanoma of the skin 25010 4 3.01 - - 4 8.16 - - 
Prostate 28010 9 6.77 - - 11 22.45 - - 
Testis 28020 2 1.50 - - 2 4.08 - - 
Urinary bladder 29010 - - - - 1 2.04 - - 
Kidney and renal pelvis 29020 2 1.50 - - 2 4.08 - - 
Ureter 29030 1 0.75 - - 1 2.04 - - 
Brain 31010 1 0.75 - - 1 2.04 - - 
Thyroid 32010 3 2.26 - - 3 6.12 - - 
Hodgkin lymphoma - nodal 33011 3 2.26 - - 3 6.12 3 2.73 
Non-Hodgkin lymphoma - nodal 33041 8 6.02 8 8.79 - - 9 8.18 
Non-Hodgkin lymphoma - extranodal 33042 11 8.27 11 12.09 - - 13 11.82 
Myeloma 34000 1 0.75 - - 1 2.04 - - 
Kaposi sarcoma 36020 70 52.63 72 79.12 - - 72 65.45 
Miscellaneous 37000 3 2.26 - - 3 6.12 - - 


























Table 5: Univariable Exact Poisson Regression – Any Cancer Diagnosis 
Predictor Events Person-Years IRR (95% CI) 
Age       
<35 31 1961.36 1.00 (REF) 
35-44 49 2927.18 1.04 (0.65-1.69) 
45-54 29 2587.29 0.71 (0.41-1.22) 
55-64 21 1041.29 1.28 (0.70-2.29) 
≥65 3 171.88 1.10 (0.22-3.54) 
<35 31 1961.36 1.00 (REF) 
35-44 49 2927.18 1.04 (0.65-1.69) 
45-54 29 2587.29 0.71 (0.41-1.22) 
≥55 24 1213.16 1.25 (0.70-2.20) 
TP53 genotype 
CC 18 1376.04 1.00 (REF) 
CG 19 1323.02 1.10 (0.55-2.22) 
GG 4 497.12 0.62 (0.15-1.87) 
CC/CG 37 2699.06 1.00 (REF) 
GG 4 497.12 0.59 (0.15-1.63) 
Missing 92 5537.81   
TLR8 genotype 
G* 42 2425.88 1.00 (REF) 
A* 91 6308.11 0.83 (0.57-1.23) 
Race 
White 116 7205.89 1.00 (REF) 
Black 12 959.32 0.78 (0.39-1.41) 
Latin/Hispanic 4 484.62 0.51 (0.14-1.35) 
Other 1 84.16 0.74 (0.02-4.19) 
White 116 7205.89 1.00 (REF) 
Black 12 959.32 0.78 (0.39-1.41) 
Other 5 568.78 0.55 (0.17-1.31) 
Non-White 17 1528.11 1.00 (REF) 
White 116 7205.89 1.45 (0.87-2.57) 
BMI (kg/m2; lagged two years) 
<25 60 3085.49 1.00 (REF) 
25-30 18 1505.84 0.61 (0.34-1.06) 
>30 8 502.55 0.82 (0.34-1.72) 
<25 60 3085.49 1.00 (REF) 
≥25 26 2008.39 0.67 (0.40-1.07) 
Missing 47 3640.12   
Alcohol consumption (drinks per week; lagged two years) 
0 11 810.50 1.00 (REF) 
1-3 44 2336.75 1.39 (0.71-2.98) 
4-13 27 1686.51 1.18 (0.57-2.64) 
>13 8 438.11 1.35 (0.47-3.67) 
0-3 55 3147.25 1.00 (REF) 
>3 35 2124.62 0.94 (0.60-1.47) 








Table 5: Univariable Exact Poisson Regression – Any Cancer Diagnosis 
(continued) 
Predictor Events Person-Years IRR (95% CI) 
Smoking status (lagged two years) 
Never 29 1633.95 1.00 (REF) 
Former 34 2080.94 0.92 (0.54-1.57) 
Current 27 1554.28 0.98 (0.56-1.71) 
Never 29 1633.95 1.00 (REF) 
Former or Current 61 3635.22 0.95 (0.60-1.53) 
Missing 43 3464.82   
Cumulative pack-years smoking history (lagged two years) 
<10.0 51 3147.89 1.00 (REF) 
10.0-19.9 5 562.18 0.55 (0.17-1.37) 
20.0-30.0 11 438.69 1.55 (0.73-3.01) 
>30.0 20 1074.37 1.15 (0.65-1.96) 
Missing 46 3510.90   
Smoking (lagged two years) 
Never 29 1633.95 1.00 (REF) 
≤30 pack-year history 38 2514.81 0.85 (0.51-1.43) 
>30 pack-year history 20 1074.37 1.05 (0.56-1.92) 
Missing 46 5024.81   
CD4+ count (cells/mm3; lagged two years) 
<200 15 332.79 1.00 (REF) 
200-349 20 720.79 0.62 (0.30-1.29) 
350-500 21 1128.71 0.41 (0.20-0.86) 
>500 32 2990.27 0.24 (0.12-0.47) 
<350 35 1053.58 1.00 (REF) 
≥350 53 4118.98 0.39 (0.25-0.61) 
Missing 45 3561.44   
Viral load (copies/mm3; lagged two years) 
<1000 17 2341.57 1.00 (REF) 
≥1000 62 2400.08 3.56 (2.05-6.49) 
Missing 54 3992.35   
HAART (lagged two years) 
No 109 5709.30 1.00 (REF) 
Yes 11 1704.63 0.34 (0.16-0.63) 
Missing 13 1320.07   
HAART + Viral load (copies/mm3; lagged two years) 
Not on HAART 109 5709.30 1.00 (REF) 
On HAART, HIV viral load ≥1000 1 197.55 0.27 (0.01-1.51) 
On HAART, HIV viral load <1000 10 1436.19 0.36 (0.17-0.90) 
Missing 13 1390.96   
Treatment era 
1984-1995 89 4058.78 1.00 (REF) 
1996-2014 44 4675.21 0.43 (0.29-0.62) 
1984-1995 89 4058.78 1.00 (REF) 
1996-2001 16 1630.01 0.45 (0.25-0.77) 
2002-2014 28 3045.21 0.42 (0.26-0.65) 








Table 6: Univariable Exact Poisson Regression – AIDS-Defining Cancers 
Predictor Events Person-Years IRR (95% CI) 
Age       
<35 29 1966.46 1.00 (REF) 
35-44 41 2989.48 0.93 (0.56-1.55) 
45-54 16 2640.42 0.41 (0.21-0.78) 
55-64 7 1109.35 0.43 (0.16-1.00) 
≥65 1 200.17 0.34 (0.01-2.04) 
<35 29 1966.46 1.00 (REF) 
35-44 41 2989.48 0.93 (0.56-1.55) 
45-54 16 2640.42 0.41 (0.21-0.78) 
≥55 8 1309.52 0.41 (0.16-0.93) 
TP53 genotype 
CC 13 1416.56 1.00 (REF) 
CG 15 1328.47 1.23 (0.55-2.81) 
GG 3 498.28 0.66 (0.12-2.39) 
CC/CG 28 2745.03 1.00 (REF) 
GG 3 498.28 0.59 (0.11-1.91) 
Missing 63 5662.56   
TLR8 genotype 
G* 30 2493.95 1.00 (REF) 
A* 64 6411.92 0.83 (0.53-1.33) 
Race 
White 81 7359.40 1.00 (REF) 
Black 8 977.69 0.74 (0.31-1.54) 
Latin/Hispanic 4 484.62 0.75 (0.20-2.00) 
Other 1 84.16 1.08 (0.03-6.19) 
White 81 7359.40 1.00 (REF) 
Black 8 977.69 0.74 (0.31-1.54) 
Other 5 568.78 0.80 (0.25-1.94) 
Non-White 13 1546.47 1.00 (REF) 
White 81 7359.40 1.31 (0.72-2.56) 
BMI (kg/m2; lagged two years) 
<25 42 3142.43 1.00 (REF) 
25-30 14 1542.53 0.68 (0.34-1.27) 
>30 3 522.59 0.43 (0.09-1.34) 
<25 42 3142.43 1.00 (REF) 
≥25 17 2065.12 0.62 (0.33-1.11) 
Missing 35 3698.32   
Alcohol consumption (drinks per week; lagged two years) 
0 7 829.51 1.00 (REF) 
1-3 29 2406.57 1.43 (0.61-3.86) 
4-13 18 1715.39 1.24 (0.50-3.52) 
>13 6 443.16 1.60 (0.45-5.58) 
0-3 36 3236.08 1.00 (REF) 
>3 24 2158.54 1.00 (0.57-1.72) 








Table 6: Univariable Exact Poisson Regression – AIDS-Defining Cancers 
(continued) 
Predictor Events Person-Years IRR (95% CI) 
Smoking status (lagged two years) 
Never 19 1668.86 1.00 (REF) 
Former 21 2148.17 0.86 (0.44-1.69) 
Current 20 1574.91 1.12 (0.57-2.21) 
Never 19 1668.86 1.00 (REF) 
Former or Current 41 3723.07 0.97 (0.55-1.76) 
Missing 34 3513.94   
Cumulative pack-years smoking history (lagged two years) 
<10.0 35 3222.17 1.00 (REF) 
10.0-19.9 3 569.78 0.48 (0.10-1.54) 
20.0-30.0 7 442.36 1.46 (0.55-3.33) 
>30.0 12 1111.58 0.99 (0.47-1.96) 
Missing 37 3559.99   
Smoking (lagged two years) 
Never 19 1668.86 1.00 (REF) 
≤30 pack-year history 26 2565.45 0.89 (0.47-1.70) 
>30 pack-year history 12 1111.58 0.95 (0.42-2.06) 
Missing 37 3559.99   
CD4+ count (cells/mm3; lagged two years) 
<200 10 344.17 1.00 (REF) 
200-349 15 734.61 0.70 (0.30-1.75) 
350-500 15 1145.30 0.45 (0.19-1.12) 
>500 19 3071.05 0.21 (0.09-0.51) 
<350 25 1078.78 1.00 (REF) 
≥350 34 4216.35 0.35 (0.20-0.61) 
Missing 35 3610.74   
Viral load (copies/mm3; lagged two years) 
<1000 3 2427.72 1.00 (REF) 
≥1000 50 2430.63 16.65 (5.38-83.44) 
Missing 41 4047.53   
HAART (lagged two years) 
No 87 5748.32 1.00 (REF) 
Yes 0 1791.91 0.03 (undefined-0.14) 
Missing 7 1365.65   
HAART + Viral load (copies/mm3; lagged two years) 
Not on HAART 87 5748.32 1.00 (REF) 
On HAART, HIV viral load ≥1000 0 205.08 0.22 (0.00-1.21) 
On HAART, HIV viral load <1000 0 1514.28 0.03 (0.00-0.16) 
Missing 7 1438.20   
Treatment era 
1984-1995 80 4074.69 1.00 (REF) 
1996-2014 14 4831.19 0.15 (0.08-0.26) 
1984-1995 80 4074.69 1.00 (REF) 
1996-2001 8 1654.77 0.25 (0.10-0.51) 
2002-2014 6 3176.41 0.10 (0.03-0.22) 








Table 7: Univariable Exact Poisson Regression – Non-AIDS-Defining Cancers 
Predictor Events Person-Years IRR (95% CI) 
Age       
<35 3 1988.60 1.00 (REF) 
35-44 11 3032.59 2.40 (0.64-13.42) 
45-54 16 2666.69 3.98 (1.14-21.30) 
55-64 15 1084.16 9.17 (2.59-49.42) 
≥65 4 177.62 14.93 (2.53-101.91) 
<35 3 1988.60 1.00 (REF) 
35-44 11 3032.59 2.40 (0.64-13.42) 
45-54 16 2666.69 3.98 (1.14-21.30) 
≥55 19 1261.78 9.98 (2.94-52.67) 
TP53 genotype 
CC 6 1416.29 1.00 (REF) 
CG 6 1336.06 1.06 (0.28-3.97) 
GG 1 495.43 0.48 (0.01-3.93) 
CC/CG 12 2752.35 1.00 (REF) 
GG 1 495.43 0.46 (0.01-3.13) 
Missing 36 5701.88   
TLR8 genotype 
G* 16 2483.99 1.00 (REF) 
A* 33 6465.67 0.79 (0.42-1.54) 
Race 
White 44 7424.10 1.00 (REF) 
Black 5 959.79 0.88 (0.27-2.21) 
Latin/Hispanic 0 481.55 0.24 (0.00-1.35) 
Other 0 84.22 1.40 (0.00-7.71) 
White 44 7424.10 1.00 (REF) 
Black 5 959.79 0.88 (0.27-2.21) 
Other 0 565.77 0.21 (0.00-1.15) 
Non-White 5 959.79 1.00 (REF) 
White 44 7424.10 1.81 (0.72-5.84) 
BMI (kg/m2; lagged two years) 
<25 23 3085.49 1.00 (REF) 
25-30 5 1505.84 0.45 (0.13-1.21) 
>30 5 502.55 1.37 (0.41-3.68) 
<25 23 3085.49 1.00 (REF) 
≥25 10 2046.41 0.68 (0.29-1.47) 
Missing 16 3640.12   
Alcohol consumption (drinks per week; lagged two years) 
0 6 833.72 1.00 (REF) 
1-3 17 2421.62 0.98 (0.37-3.02) 
4-13 12 1722.80 0.97 (0.34-3.14) 
>13 2 439.04 0.63 (0.06-3.54) 
0-3 23 3255.34 1.00 (REF) 
>3 14 2161.84 0.92 (0.44-1.86) 








Table 7: Univariable Exact Poisson Regression – Non-AIDS-Defining Cancers 
(continued) 
Predictor Events Person-Years IRR (95% CI) 
Smoking status (lagged two years) 
Never 11 1694.40 1.00 (REF) 
Former 17 2147.42 1.22 (0.54-2.88) 
Current 9 1572.67 0.88 (0.32-2.34) 
Never 11 1694.40 1.00 (REF) 
Former or Current 26 3720.09 1.08 (0.51-2.41) 
Missing 12 3535.17   
Cumulative pack-years smoking history (lagged two years) 
<10.0 19 3261.16 1.00 (REF) 
10.0-19.9 2 564.26 0.61 (0.07-2.52) 
20.0-30.0 5 455.53 1.88 (0.55-5.22) 
>30.0 11 1083.15 1.74 (0.75-3.85) 
Missing 12 3585.57   
Smoking (lagged two years) 
Never 11 1694.40 1.00 (REF) 
≤30 pack-year history 15 2584.44 0.89 (0.38-2.15) 
>30 pack-year history 11 1083.15 1.56 (0.62-3.98) 
Missing 22 3587.68   
CD4+ count (cells/mm3; lagged two years) 
<200 7 375.90 1.00 (REF) 
200-349 5 755.59 0.36 (0.09-1.30) 
350-500 7 1161.34 0.32 (0.10-1.08) 
>500 17 3018.34 0.30 (0.12-0.86) 
<350 12 1131.49 1.00 (REF) 
≥350 24 4179.68 0.54 (0.26-1.19) 
Missing 13 3638.49   
Viral load (copies/mm3; lagged two years) 
<1000 16 2392.22 1.00 (REF) 
≥1000 17 2476.20 1.03 (0.49-2.17) 
Missing 16 4081.24   
HAART (lagged two years) 
No 28 5809.07 1.00 (REF) 
Yes 14 1767.45 1.64 (0.80-3.23) 
Missing 7 1373.15   
HAART + Viral load (copies/mm3; lagged two years) 
Not on HAART 28 5809.07 1.00 (REF) 
On HAART, HIV viral load ≥1000 2 208.27 1.99 (0.23-7.90) 
On HAART, HIV viral load <1000 12 1482.14 1.68 (0.78-3.41) 
Missing 7 1450.19   
Treatment era 
1984-1995 13 4116.44 1.00 (REF) 
1996-2014 36 4833.22 2.36 (1.22-4.85) 
1984-1995 13 4116.44 1.00 (REF) 
1996-2001 11 1697.46 2.05 (0.83-4.96) 
2002-2014 25 3135.76 2.52 (1.24-5.37) 








Table 8: Univariable Exact Poisson Regression – Infection-Related Cancers 
Predictor Events Person-Years IRR (95% CI) 
Age 
<35 30 1964.85 1.00 (REF) 
35-44 45 2984.13 0.99 (0.61-1.62) 
45-54 26 2611.13 0.65 (0.37-1.14) 
55-64 8 1089.73 0.48 (0.19-1.07) 
≥65 1 197.79 0.33 (0.01-1.99) 
<35 30 1964.85 1.00 (REF) 
35-44 45 2984.13 0.99 (0.61-1.62) 
45-54 26 2611.13 0.65 (0.37-1.14) 
≥55 9 1287.53 0.46 (0.19-0.99) 
TP53 genotype 
CC 16 1396.40 1.00 (REF) 
CG 19 1322.47 1.25 (0.61-2.61) 
GG 3 498.28 0.53 (0.10-1.84) 
CC/CG 35 2718.88 1.00 (REF) 
GG 3 498.28 0.47 (0.09-1.48) 
Missing 72 5630.47   
TLR8 genotype 
G* 34 2482.75 1.00 (REF) 
A* 76 6364.89 0.87 (0.57-1.35) 
Race 
White 96 7313.58 1.00 (REF) 
Black 9 965.27 0.71 (0.32-1.41) 
Latin/Hispanic 4 484.62 0.63 (0.17-1.66) 
Other 1 84.16 0.91 (0.02-5.17) 
White 96 7313.58 1.00 (REF) 
Black 9 965.27 0.71 (0.32-1.41) 
Other 5 568.78 0.67 (0.21-1.62) 
Non-White 14 1534.05 1.00 (REF) 
White 96 7313.58 1.44 (0.82-2.73) 
BMI (kg/m2; lagged two years) 
<25 51 3114.82 1.00 (REF) 
25-30 14 1542.03 0.55 (0.28-1.02) 
>30 6 507.14 0.72 (0.25-1.68) 
<25 51 3114.82 1.00 (REF) 
>25 20 2049.17 0.60 (0.34-1.02) 
Missing 39 3683.65   
Alcohol consumption (drinks per week; lagged two years) 
0 8 827.02 1.00 (REF) 
1-3 35 2387.25 1.52 (0.39-3.78) 
4-13 23 1697.22 1.40 (0.60-3.62) 
>13 7 437.81 1.65 (0.51-5.22) 
0-3 43 3214.28 1.00 (REF) 
>3 30 2135.03 1.05 (0.64-1.71) 








Table 8: Univariable Exact Poisson Regression – Infection-Related Cancers 
(continued) 
Predictor Events Person-Years IRR (95% CI) 
Smoking status (lagged two years) 
Never 22 1653.48 1.00 (REF) 
Former 26 2137.43 0.91 (0.50-1.69) 
Current 25 1555.70 1.21 (0.65-2.25) 
Never 22 1653.48 1.00 (REF) 
Former or Current 51 3693.13 1.04 (0.62-1.80) 
Missing 37 3501.02   
Cumulative pack-years smoking history (lagged two years) 
<10.0 40 3202.62 1.00 (REF) 
10.0-19.9 5 562.18 0.71 (0.22-1.80) 
20.0-30.0 10 438.39 1.83 (0.81-3.72) 
>30.0 15 1097.37 1.09 (0.56-2.02) 
Missing 40 3547.07   
Smoking (lagged two years) 
Never 22 1653.48 1.00 (REF) 
≤30 pack-year history 15 1000.57 1.13 (0.54-2.27) 
>30 pack-year history 15 1097.37 1.03 (0.50-2.07) 
Missing 58 5096.22   
CD4+ count (cells/mm3; lagged two years) 
<200 16 335.65 1.00 (REF) 
200-349 16 725.67 0.46 (0.22-0.99) 
350-500 17 1140.67 0.31 (0.15-0.66) 
>500 23 3047.82 0.16 (0.08-0.32) 
<350 32 1061.32 1.00 (REF) 
≥350 40 4188.50 0.32 (0.19-0.52) 
Missing 38 3597.82   
Viral load (copies/mm3; lagged two years) 
<1000 5 2396.71 1.00 (REF) 
≥1000 59 2417.71 11.70 (4.74-37.35) 
Missing 46 4033.21   
HAART (lagged two years) 
No 100 5734.40 1.00 (REF) 
Yes 2 1761.12 0.07 (0.01-0.24) 
Missing 8 1352.12   
HAART + Viral load (copies/mm3; lagged two years) 
Not on HAART 100 5734.40 1.00 (REF) 
On HAART, HIV viral load ≥1000 1 201.43 0.28 (0.01-1.62) 
On HAART, HIV viral load <1000 1 1487.13 0.04 (0.01-0.22) 
Missing 8 1424.68   
Treatment era 
1984-1995 85 4070.43 1.00 (REF) 
1996-2014 25 4777.21 0.25 (0.15-0.40) 
1984-1995 85 4070.43 1.00 (REF) 
1996-2001 14 1645.39 0.41 (0.21-0.72) 
2002-2014 11 3131.82 0.17 (0.08-0.32) 








Table 9: Multivariable Exact Poisson Regression – All Outcomes 
Predictor 
Any Cancer AIDS-defining Cancer Infection-Related Cancer 
IRR (95% CI) IRR (95% CI) IRR (95% CI) 
TP53 genotype 
CC, CG 1.00 (REF) 1.00 (REF) 1.00 (REF) 
GG 0.65 (0.01-5.74) 1.01 (0.02-10.74) 0.86 (0.02-8.00) 
TLR8 genotype 
G* 1.00 (REF) 1.00 (REF) 1.00 (REF) 
A* 0.92 (0.33-2.93) 0.84 (0.22-3.90) 1.01 (0.33-3.69) 
Joint Effect (TP53GG*TLR8 A*) 
No 1.00 (REF) 1.00 (REF) 1.00 (REF) 
Yes 0.46 (0.01-42.71) 0.47 (0.01-48.55) 0.40 (0.01-39.37) 
Race 
White 1.00 (REF) 1.00 (REF) 1.00 (REF) 
Black 0.99 (0.16-3.82) 1.79 (0.27-7.87) 1.19 (0.19-4.72) 
Other 0.80 (0.02-5.27) 1.52 (0.03-11.59) 1.09 (0.03-7.53) 
BMI (kg/m2; lagged two years) 
Underweight/Normal 1.00 (REF) 1.00 (REF) 1.00 (REF) 
Overweight/Obese 0.48 (0.12-1.44) 0.19 (0.01-1.35) 0.24 (0.03-1.01) 
Smoking history (lagged two years) 
Never 1.00 (REF) 1.00 (REF) 1.00 (REF) 
≤30 pack-year history 0.78 (0.30-2.12) 0.74 (0.18-3.11) 0.95 (0.33-2.91) 
>30 pack-year history 0.39 (0.07-1.60) 0.29 (0.01-2.60) 0.53 (0.09-2.37) 
CD4+ Count (cells/mm3; lagged two years) 
<350 1.00 (REF) 1.00 (REF) 1.00 (REF) 
≥350 0.26 (0.11-0.64) 0.36 (0.09-1.32) 0.26 (0.09-0.68) 
HAART + Viral load (copies/mm3; lagged two years) 
Not on HAART 1.00 (REF) 1.00 (REF) 1.00 (REF) 
On HAART, viral load ≥1000 0.78 (0.00-4.65) 1.14 (0.00-7.42) 1.25 (0.03-8.56) 
On HAART, viral load <1000 0.49 (0.05-2.02) 0.22 (0.00-1.35) 0.19 (0.00-1.10) 
Alcohol consumption (drinks per week; lagged two years) 
0-3 N/I N/I 1.00 (REF) 
>3 N/I N/I 1.50 (0.54-4.10) 
Abbreviations: BMI – body mass index, IRR – incidence rate ratio, HAART – highly-active antiretroviral 
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